Abstract
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmogenic disease characterized by adrenergic-induced arrhythmias in the form of bidirectional and PVT. CPVT is a distinct clinical entity associated with a high mortality rate of up to 50% by the age of 30 yr. Recently, the molecular diagnostics of this disease have become increasingly important because underlying mutations can be found in more than 60% of the identified CPVT patients. Along with the fact that treatment with β-blockers has a favorable outcome in CPVT patients, and given the risk of sudden death, the identification of causative mutations in CPVT is important because it can greatly augment early diagnosis and subsequent preventive strategies. In this chapter, we describe the molecular diagnostics, as performed in our lab, of the three genes known to be involved in CPVT, the cardiac ryanodine receptor gene, the cardiac calsequestrin gene, and the inwardly rectifying potassium channel KCNJ2.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Priori, S. G., Napolitano, C., Tiso, N., et al. (2001) Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103(2), 196–200.
Priori, S. G., Napolitano, C., Memmi, M., et al. (2002) Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 106(1), 69–74.
Postma, A. V., Denjoy, I., Hoorntje, T. M., et al. (2002) Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ. Res. 91(8), e21–26.
Swan, H., Piippo, K., Viitasalo, M., et al. (1999) Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J. Am. Coll. Cardiol. 34(7), 2035–2042.
Tiso, N., Stephan, D. A., Nava, A., et al. (2001) Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum. Mol. Genet. 10(3), 189–194.
Laitinen, P. J., Brown, K. M., Piippo, K., et al. (2001) Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation, 103(4) 485–490.
Bauce, B., Rampazzo, A., Basso, C., et al. (2002) Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers. J. Am. Coll. Cardiol. 40(2), 341–349.
Postma, A. V., Denjoy, I., Kamblock, J., et al. (2005) Catecholaminergic polymorphicventricular tachycardia: RYR2 mutations, bradycardia, and follow-up of the patients. J. Med. Gen. 42, 863–870.
Meissner, G. (2002) Regulation of mammalian ryanodine receptors. Front. Biosci. 7, d2072–2080.
Lahat, H., Pras, E., Olender, T., et al. (2001) aA missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Isrel. Am. J. Hum. Genet. 69(6), 1378–1384.
Plaster, N. M., Tawil, R., Tristani-Firouzi, M., et al. (2001) Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen’s syndrome. Cell, 105(4) 511–519.
Andelfinger, G., Tapper, A. R., Welch, R. C., et al. (2002) KCNJ2 mutation results in Andersen syndrome with sex-specific cardiac and skeletal muscle phenotypes. Am. J. Hum. Genet. 716(3), 663–668.
Donaldson, M. R., Jensen, J. L., Tristani-Firouzi, M., et al. (2003) PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology 60(11), 1811–1816.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc.
About this protocol
Cite this protocol
Postma, A.V., Bhuiyan, Z.A., Bikker, H. (2006). Molecular Diagnostics of Catecholaminergic Polymorphic Ventricular Tachycardia Using Denaturing High-Performance Liquid Chromatography and Sequencing. In: Kearns-Jonker, M. (eds) Congenital Heart Disease. Methods in Molecular Medicine, vol 126. Humana Press. https://doi.org/10.1385/1-59745-088-X:171
Download citation
DOI: https://doi.org/10.1385/1-59745-088-X:171
Publisher Name: Humana Press
Print ISBN: 978-1-58829-375-6
Online ISBN: 978-1-59745-088-1
eBook Packages: Springer Protocols